CBD Oil & the Endocannabinoid System Explained
Quick Answer
Cannabidiol (CBD) is a non-intoxicating compound derived from Cannabis sativa that interacts with the body’s Endocannabinoid System (ECS). Rather than directly activating CB1 or CB2 receptors, CBD may enhance endocannabinoid tone by inhibiting the FAAH enzyme, which breaks down anandamide. Research suggests CBD also acts on serotonin 5-HT1A receptors, TRPV-1 pain channels, and PPAR-gamma nuclear receptors, potentially supporting nervous, immune, and gastrointestinal function.
At a Glance
- CBD is a negative allosteric modulator of the CB1 receptor, meaning it may reduce THC binding efficiency without producing intoxication (Laprairie et al., 2015).
- The Endocannabinoid System (ECS), discovered in the 1990s by Raphael Mechoulam and colleagues, regulates pain, mood, immunity, and gut function through CB1 and CB2 receptors.
- CBD may inhibit FAAH (fatty acid amide hydrolase), the enzyme that degrades anandamide, potentially increasing endocannabinoid signalling indirectly.
- In Australia, the Therapeutic Goods Administration (TGA) classifies low-dose CBD (up to 150 mg/day) as a Schedule 3 pharmacist-only medicine since February 2021.
- CBD inhibits CYP450 liver enzymes, which may affect the metabolism of common pharmaceuticals including warfarin, clobazam, and certain statins.
The Endocannabinoid System Explained
The Endocannabinoid System (ECS) is a biological signalling network present in virtually every tissue of the human body. Discovered in the early 1990s by Israeli chemist Raphael Mechoulam and his research team at the Hebrew University of Jerusalem, the ECS is now recognised as one of the most important regulatory systems in human physiology — regardless of whether a person ever uses cannabis [1].
The ECS consists of three core components:
| ECS Component | Examples | Primary Role |
|---|---|---|
| Endocannabinoids | Anandamide (AEA), 2-Arachidonoylglycerol (2-AG) | Signalling molecules produced on demand by the body |
| Cannabinoid Receptors | CB1 (central nervous system), CB2 (immune/peripheral) | Receive and transduce endocannabinoid signals |
| Metabolic Enzymes | FAAH (fatty acid amide hydrolase), MAGL (monoacylglycerol lipase) | Synthesise and degrade endocannabinoids after use |
CB1 and CB2 Receptors
CB1 receptors are concentrated in the central nervous system — the brain and spinal cord. They modulate neurotransmitter release, pain perception, mood, appetite, and memory. Delta-9-tetrahydrocannabinol (THC), the intoxicating component of cannabis, primarily activates CB1 receptors, which accounts for its psychoactive effects [3].
CB2 receptors are found predominantly in immune cells, the gastrointestinal tract, and peripheral tissues. They may play a key role in regulating inflammation, immune cell function, and gut barrier integrity. CB2 activation is associated with anti-inflammatory effects without the psychoactive properties linked to CB1 [4].
How CBD Differs from THC
Unlike THC, CBD does not directly bind strongly to CB1 or CB2 receptors. According to research by Robert Laprairie and colleagues published in the British Journal of Pharmacology (2015), CBD acts as a negative allosteric modulator of CB1 — meaning it changes the shape of the receptor so that THC and other agonists bind less effectively. CBD also inhibits FAAH, the enzyme that breaks down anandamide, thereby potentially increasing endocannabinoid tone indirectly [5].
This mechanism may explain why CBD does not produce intoxication: it enhances the body’s own endocannabinoid signalling rather than directly activating the receptors that produce psychoactive effects.
Beyond Cannabinoid Receptors: CBD’s Multi-Target Pharmacology
CBD interacts with at least 65 identified molecular targets beyond the classical cannabinoid receptors, according to a systematic review by Ibeas Bih and colleagues in Neurotherapeutics (2015) [6]. This multi-target pharmacology may account for the breadth of its reported effects.
Serotonin (5-HT1A) Receptors
CBD acts as a partial agonist at the 5-HT1A serotonin receptor — the same receptor targeted by buspirone (an anxiolytic medication). Research by De Mello Schier and colleagues published in CNS & Neurological Disorders Drug Targets (2014) suggests this interaction may underpin much of CBD’s anxiolytic and antidepressant-like effects observed in preclinical models [7]. It may also contribute to anti-nausea effects.
Pain and TRPV-1 Receptors
CBD activates TRPV-1 (transient receptor potential vanilloid type 1) channels — the same receptors activated by capsaicin in chilli peppers. TRPV-1 is involved in pain perception, inflammation, and body temperature regulation. Muller, Morales, and Reggio reported in Frontiers in Molecular Neuroscience (2019) that CBD’s activation of these channels may contribute to its analgesic and anti-inflammatory properties [8].
PPAR-gamma (Peroxisome Proliferator-Activated Receptors)
CBD activates PPAR-gamma receptors, which are nuclear receptors involved in lipid metabolism, insulin sensitivity, and inflammation regulation. Saoirse O’Sullivan’s review in the British Journal of Pharmacology (2016) found that PPAR activation has been associated with anti-inflammatory, neuroprotective, and anti-tumour effects in preclinical models [9].
| Receptor Target | Mechanism of Action | Associated Effects |
|---|---|---|
| 5-HT1A (Serotonin) | Partial agonist | May reduce anxiety, nausea; antidepressant-like activity |
| TRPV-1 (Vanilloid) | Channel activator (agonist) | May modulate pain perception and inflammation |
| PPAR-gamma (Nuclear) | Receptor activator | Associated with anti-inflammatory and neuroprotective effects |
| CB1 (Cannabinoid) | Negative allosteric modulator | Reduces THC binding; non-intoxicating |
| FAAH (Enzyme) | Inhibitor | May increase anandamide levels |
Accessing CBD in Australia
The Therapeutic Goods Administration (TGA) regulates all CBD products in Australia under the Therapeutic Goods Act 1989. Since February 2021, low-dose CBD products (up to 150 mg/day) have been available over the counter at pharmacies as Schedule 3 (pharmacist-only) medicines, though product availability has been limited in practice [10].
Higher-dose CBD and CBD/THC combination products remain Schedule 4 (prescription only) or Schedule 8 (controlled), depending on THC content. Access to these products typically occurs through:
| Access Pathway | Description | Typical Use |
|---|---|---|
| Authorised Prescriber (AP) | Doctors with individual TGA authorisation to prescribe medicinal cannabis | Ongoing prescribing for specific conditions |
| Special Access Scheme (SAS-B) | TGA pathway allowing doctors to prescribe unapproved therapeutic goods for individual patients | Case-by-case patient access |
| Approved Product Pathway | TGA-approved products prescribed through standard channels (e.g., Epidyolex for epilepsy) | Specific approved indications |
It is important to note that CBD products sold online without prescription may not meet Australian regulatory standards for quality, purity, or accurate labelling [11].
Clinical Endocannabinoid Deficiency: An Emerging Theory
Neurologist Ethan Russo proposed the Clinical Endocannabinoid Deficiency (CED) theory in 2004, later revisited in Cannabis and Cannabinoid Research (2016). The theory suggests that conditions such as migraine, fibromyalgia, and irritable bowel syndrome (IBS) may share a common underlying pathology: insufficient endocannabinoid tone [14].
McPartland, Guy, and Di Marzo published a systematic review in PLoS One (2014) identifying lifestyle interventions that may support endocannabinoid function, including aerobic exercise, omega-3 fatty acid intake, stress reduction techniques, and adequate sleep [15]. This perspective aligns with functional medicine approaches that address root causes rather than isolated symptoms.
When to Consider Professional Review
CBD is not a standalone solution and may work best when integrated into a broader health strategy. Consider professional guidance when:
- You are managing chronic pain, anxiety, or sleep disruption that has not responded adequately to conventional approaches
- You are taking medications that may interact with CBD — CBD inhibits CYP450 enzymes (particularly CYP3A4 and CYP2D6), affecting the metabolism of many pharmaceuticals including warfarin, clobazam, and certain antidepressants [12]
- You want to understand whether ECS dysfunction may be contributing to your symptoms
- You are considering CBD as part of a functional medicine approach to mood, neurological, or immune concerns
A qualified practitioner can help determine whether CBD is appropriate for your situation, navigate the regulatory landscape, and ensure it is integrated safely with any existing medications or supplements [13].
Next Steps
- Understand CBD’s legal status in Australia: Familiarise yourself with current TGA scheduling and the difference between over-the-counter and prescription pathways.
- Consult a healthcare professional before use: CBD interacts with CYP450 enzymes and can affect the metabolism of many medications. Professional guidance is essential for safe integration.
- Consider CBD as part of a broader functional medicine framework: Rather than treating CBD as an isolated supplement, explore how endocannabinoid system function fits within your overall health picture.
Frequently Asked Questions
Key Insights
- CBD is a non-intoxicating cannabinoid that may enhance the body’s own endocannabinoid signalling rather than directly activating psychoactive receptors.
- CBD acts on multiple pathways beyond cannabinoid receptors, including serotonin (5-HT1A), pain (TRPV-1), and metabolic (PPAR-gamma) targets.
- CB2 receptors link the endocannabinoid system to immune regulation and gut barrier integrity, relevant to inflammatory and gastrointestinal conditions.
- Regulatory oversight is essential — CBD is a scheduled medicine in Australia under the TGA and interacts with CYP450 drug metabolism pathways.
- Ethan Russo’s Clinical Endocannabinoid Deficiency theory suggests migraine, fibromyalgia, and IBS may share a common endocannabinoid dysfunction.
Citable Takeaways
- CBD acts as a negative allosteric modulator of the CB1 receptor, reducing THC binding efficiency without producing intoxication, according to Laprairie et al. in the British Journal of Pharmacology (2015).
- The Endocannabinoid System, discovered by Raphael Mechoulam’s team in the early 1990s, consists of endocannabinoids (anandamide and 2-AG), receptors (CB1 and CB2), and metabolic enzymes (FAAH and MAGL).
- CBD may interact with at least 65 molecular targets including 5-HT1A serotonin receptors, TRPV-1 pain channels, and PPAR-gamma nuclear receptors, according to Ibeas Bih et al. in Neurotherapeutics (2015).
- Since February 2021, the Australian TGA has classified low-dose CBD (up to 150 mg/day) as Schedule 3, available over the counter at pharmacies without a prescription.
- CBD inhibits CYP450 liver enzymes (particularly CYP3A4 and CYP2D6), which may affect the metabolism of common medications including warfarin and clobazam, as reported by Nasrin et al. in Clinical Pharmacology and Therapeutics (2021).
- Ethan Russo’s Clinical Endocannabinoid Deficiency theory, published in Cannabis and Cannabinoid Research (2016), proposes that migraine, fibromyalgia, and IBS may share a common pathology of insufficient endocannabinoid tone.
Explore a Holistic Approach to Health
If you are exploring underlying contributors to chronic inflammation, mood dysregulation, or complex health patterns, professional guidance at Elemental Health and Nutrition can help place emerging therapies into proper context.
References
- Mechoulam R, Parker LA. The endocannabinoid system and the brain. Annu Rev Psychol. 2013;64:21-47.
- Lu HC, Mackie K. An introduction to the endogenous cannabinoid system. Biol Psychiatry. 2016;79(7):516-25.
- Zou S, Kumar U. Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. Int J Mol Sci. 2018;19(3):833.
- Turcotte C, Blanchet MR, Laviolette M, Bhomia NK. The CB2 receptor and its role as a regulator of inflammation. Cell Mol Life Sci. 2016;73(23):4449-70.
- Laprairie RB, Bagher AM, Kelly MEM, Bhomia NK. Cannabidiol is a negative allosteric modulator of the cannabinoid CB1 receptor. Br J Pharmacol. 2015;172(20):4790-805.
- Ibeas Bih C, Chen T, Nunn AVW, et al. Molecular targets of cannabidiol in neurological disorders. Neurotherapeutics. 2015;12(4):699-730.
- De Mello Schier AR, De Oliveira Ribeiro NP, Coutinho DS, et al. Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa. CNS Neurol Disord Drug Targets. 2014;13(6):953-60.
- Muller C, Morales P, Reggio PH. Cannabinoid ligands targeting TRP channels. Front Mol Neurosci. 2019;11:487.
- O’Sullivan SE. An update on PPAR activation by cannabinoids. Br J Pharmacol. 2016;173(12):1899-910.
- Therapeutic Goods Administration (TGA). Over-the-counter access to low dose cannabidiol. Australian Government Department of Health; 2020.
- Suraev AS, Marshall NS, Vandrey R, et al. Cannabinoid therapies in the management of sleep disorders: a systematic review of preclinical and clinical studies. Sleep Med Rev. 2020;53:101339.
- Nasrin S, Watson CJW, Perez-Paramo YX, Lazarus P. Cannabinoid metabolites as inhibitors of major hepatic CYP450 enzymes, with implications for cannabis-drug interactions. Clin Pharmacol Ther. 2021;109(6):1506-17.
- Millar SA, Stone NL, Yates AS, O’Sullivan SE. A systematic review on the pharmacokinetics of cannabidiol in humans. Front Pharmacol. 2018;9:1365.
- Russo EB. Clinical endocannabinoid deficiency reconsidered: current research supports the theory in migraine, fibromyalgia, irritable bowel, and other treatment-resistant syndromes. Cannabis Cannabinoid Res. 2016;1(1):154-65.
- McPartland JM, Guy GW, Di Marzo V. Care and feeding of the endocannabinoid system: a systematic review of potential clinical interventions that upregulate the endocannabinoid system. PLoS One. 2014;9(3):e89566.
